



Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT 1 JULY 2013

Introduction

The purpose of this report is to inform the Ministry of Health and all stakeholders of the stock levels in the country in order for appropriate logistics decisions to be made and implemented. This report highlights challenges, bottlenecks and recommends potential solutions to mitigate stock outs and expiries of ARVs & HIV test kits, ACTs, Anti-TB medicines, Reproductive Health items, selected Laboratory commodities, Vaccines and selected medicines for Opportunistic Infections.

It can be used to:

- Act as an early warning indicator for potential stock outs and possible expiries of EMHS
- Identify challenges and recommendations to avert supply interruptions
- Encourage preparation and sharing of joint supply plans with stakeholders
- Identify strategies for regularly reviewing supply plans for all the commodities
- Encourage donors to honor their commitments in terms of quantities of products expected, timeliness of deliveries and flexibility

Summary of Key Issues

1. HIV/AIDS Commodities

- TDF-based formulations are well stocked nationally; TDF/3TC/EFV will be opened up for ART use, in addition to PMTCT, starting in July 2013. NMS is low on adult AZT based formulations and EFV 600 mg. Orders have been placed to fill the public sector ARV gap up to December 2013 and deliveries are expected to arrive in the country between August and October 2013. Deliveries from Quality Chemicals Industry Limited (QCIL) are also expected at the end of July 2013 and SCMS shipments expected to arrive at JMS in August 2013 been redirected to NMS. UNITAID will place orders in July for the paediatric drugs that are low in stock at NMS. An order for NVP syrup for eMTCT has been placed to replenish stock at NMS. In the interim, some stock of NVP syrup will be transferred from JMS to NMS. At MAUL, EFV 100mg is available to be used in place of EFV 200mg which is stocked out but with pipeline expected by the end of July 2013.
- Increased uptake of the NVP 50mg tablets versus the syrup for ART is recommended and interwarehouse transfer of the NVP 50mg tablets shall be initiated to avoid expiries.

2. Medicines for Opportunistic Infections

- MAUL has adequate stock of fluconazole tablets. Pfizer has approved a procurement request from Uganda to meet the needs for all the warehouses for 12 months, with delivery dates to be confirmed and expedited. Cotrimoxazole 960mg tablets is low on stock at NMS and MAUL.
- No expiry risk to date.

3. Antimalarials

- Central level stock for ACTs at NMS appear low, however preliminary Medicines Management Supervision reports indicate ~70% facilities are adequately stocked (2+ months). Additional orders have been placed through GF for central level and products are expected by Oct-Dec 2013. Deliveries from Quality Chemicals are also expected in July and October 2013. NMS continues to call off quinine injection, artesunate injection and SP from the framework contract.
- No expiry risk to date.

4. Laboratory

- There are currently low stock levels at NMS for key laboratory commodities. Procurement for Determine test kits from PEPFAR and Global Fund underway. PEPFAR procurement of CD4 commodities for the public sector underway. Further DFID funding towards lab commodities has been confirmed and allocated towards HIV test kits, Hematology, clinical Chemistry and General reagents. For JMS, deliveries from PEPFAR are to arrive in Aug-Sept 2013 to provide for remainder of year.

5. Anti TB Medicines

- Although central level stock of RH and RHE is low, most health facilities are well stocked. Consignments of RH paed and RHE that arrived recently from GF are to be verified. Global Fund orders have been approved and procurement is underway.
- Capreomycin, Cycloserine, and Paser at risk of expiry. Quantities at risk of expiry will be loaned other countries.

6. Reproductive Health

- Key commodities are well stocked. Pipeline for products that are stocked out to be monitored.
- No expiry risk to date.

7. Vaccines

- Although the polio trivalent stock is inadequate, the bivalent vaccine is sufficiently stocked to cover the current need - no risk of stock outs.
- No expiry risks to date.

8. Tracer Medicines

- Procurement of ORS to be expedited.
- No expiry risk to date.




Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS OF 1 JULY 2013

1. HIV/AIDS Commodities


a) ARVs - Adult

Stock Status (July 1'13) & Total confirmed deliveries in next three months (July to Sept'13)


National




NMS



JMS




MAUL




Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

b) ARVs - Paediatric


National




NMS



JMS



MAUL



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Risk of stock out in next three months

Legend

Stock out risk	Below 2 Months of Stock
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 Months of Stock
Adequate stock	Within 3-6 months of stock
Stocked out	No product in warehouse


Formulation	NMS	JMS	MAUL	Comment
Adult				
AZT/3TC/NVP 300/150/200 mg	Red	Green	Green	NMS - All GF consignment delivered. QC and PEPFAR deliveries for NMS expected in July and August respectively.
AZT/3TC 300/150 mg	Red	Green	Green	NMS - All GF consignment delivered. QC and PEPFAR deliveries for NMS expected in July and August respectively.
TDF/3TC 300/300 mg	Green	Green	Green	JMS pipeline expected in August from PEPFAR
TDF/3TC/EFV 300/300/600 mg	Green	Green	Green	NMS - Very well stocked. Supply to be opened up to other patients other than PMTCT.
EFV 600 mg	Red	Green	Green	NMS - All GF consignment delivered. QC and PEPFAR deliveries for NMS expected in July and August respectively.
NVP 200 mg	Green	Green	Green	
ATV/r 300/100 mg	Green	Yellow	Yellow	
LPV/r 200/50 mg	Yellow	Green	Green	
Paediatric				
AZT/3TC/NVP 60/30/50 mg	Yellow	Purple	Green	NMS - UNITAID will place orders in July 2013, expected delivery in Sept-Oct 2013
AZT/3TC 60/30 mg	Red	Green	Green	NMS - UNITAID will place orders in July 2013, expected delivery in Sept-Oct 2013. Inter-warehouse transfer to be initiated.
ABC/3TC 60/30 mg	Yellow	Green	Green	NMS - UNITAID will place orders in July 2013, expected delivery in Sept-Oct 2013
EFV 200 mg	Green	Green	Red	MAUL-EFV 100mg will be used and EFV 200mg pipeline expected end of July 2013
NVP 50 mg	Green	Purple	Green	Uptake of NVP 50 mg to be encouraged at facility level
NVP 100 ml / NVP 240 ml	Red	Green	Green	Order placed by PEPFAR to replenish stock at NMS. All GF shipments for 2013 delivered.
LPV/r 100/25 mg	Green	Green	Green	
LPV/r 80/20 mg/ml	Black	Black	Green	NMS - UNITAID will place orders in July 2013, expected delivery in Sept-Oct 2013. Inter-warehouse transfer to be initiated.

Stock Out Risks and Recommendation/Action :	TDF-based formulations are well stocked nationally; TDF/3TC/EFV will be opened up for ART use, in addition to PMTCT, starting in July 2013. NMS is low on adult AZT based formulations and EFV 600 mg. Orders have been placed to fill the public sector ARV gap up to December 2013 and deliveries are expected to arrive in the country between August and October 2013. Deliveries from Quality Chemicals Industry Limited (QCIL) are also expected at the end of July 2013 and SCMS shipments expected to arrive at JMS in August 2013 been redirected to NMS. UNITAID will place orders in July for the paediatric drugs that are low in stock at NMS. An order for NVP syrup for eMTCT has been placed to replenish stock at NMS. In the interim, some stock of NVP syrup will be transferred from JMS to NMS. At MAUL, EFV 100mg is available to be used in place of EFV 200mg which is stocked out but with pipeline expected by the end of July 2013. Further procurement will be initiated to fill any gaps between September to December 2013.
Expiry Risks and Recommendation/Action :	Increased uptake of the NVP 50mg tablets versus the syrup for ART is recommended and interwarehouse transfer of the NVP 50mg tablets shall be initiated to avoid expiries.


2. Medicines for Opportunistic Infections

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)


National




NMS



JMS



MAUL



Please see Months of Stock over 6 Months to view months of stock including deliveries and consumption over time.

Legend

Stock out risk	Below 2 Months of stock
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock (3 months)
Below min	Below 3 MOS
Adequate stock	Within 3-6 Months
Stocked out	No product in warehouse

Risk of stock out in next three months

Formulation	NMS	JMS	MAUL	Comments
Fluconazole 200mg(Diflucan)	Green	Green	Green	Orders will be placed in July 2013
Fluconazole 2mg/ml I.V. infusion 100ml (Diflucan)	Green	Green	Green	Low utilisation. Orders will be placed in July 2013
Fluconazole 50mg/5ml oral suspension (Diflucan)	Green	Green	Green	Low utilisation. Orders will be placed in July 2013
Cotrimoxazole 960mg Tab	Yellow	Green	Red	GF deliveries will be made in July 2013

**Stock Out Risks and
Recommendation/Action :**

MAUL has adequate stock of fluconazole tablets. Pfizer has approved a procurement request from Uganda to meet the needs for all the warehouses for 12 months, with delivery dates to be confirmed and expedited. Cotrimoxazole 960mg tablets is low on stock at NMS and MAUL, but deliveries are expected in July 2013 for NMS and August 2013 for MAUL. JMS has adequate stock.


**Expiry Risks and
Recommendation/Action :**

No expiry risk to date.


3. Antimalarials

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul-Sept'13)


National



NMS



JMS



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Legend

Stock out risk	Below 2 Months of Stock
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 Months of Stock
Adequate stock	Within 3-6 Months of Stock
Stocked out	No product in warehouse

Risk of stock out in next three months


Formulation	NMS	JMS	Comments
ACT 20/120mg tab, 24 pack	Green	Green	
ACT 20/120mg tab, 18 pack	Red	Green	NMS-Additional orders placed through GF. Products to be expected by Oct - Dec 2013.
ACT 20/120mg tab, 12 pack	Red	Green	
ACT 20/120mg tab, 6 pack	Red	Green	
Artesunate Injection 60mg/ml	Yellow	Green	NMS and PMI orders have been placed. NMS pipeline expected in July 2013
Quinine HCl injection, 600mg/2ml	Red	Green	NMS to call off product from the framework contract
Sulphadoxine-Pyrimethamine 500/25mg tab*	Yellow	Green	NMS to call off product from the framework contract

Stock Out Risks and Recommendation/Action :	Central level stock for ACTs at NMS appear low, however preliminary Medicines Management Supervision reports indicate ~70% facilities are adequately stocked (2+ months) . Additional orders have been placed through GF for central level and products are expected by Oct-Dec 2013. Deliveries from Quality Chemicals are also expected in July and October 2013. NMS continues to call off quinine injection, artesunate injection and SP from the framework contract.
Expiry Risks and Recommendation/Action :	JMS is well stocked with ACTs. No expiry risk to date.


4. Laboratory

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)


National




NMS



JMS



MAUL



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Risk of stock out in next three months

Legend

Stock out risk	Below 2 MOS
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 MOS
Adequate stock	Within Min-Max
Stocked out	No product in warehouse

Formulation	NMS	JMS	MAUL	Comments
Malaria Rapid diagnostic kits			N/A	
Determine HIV 1/2 Rapid Test Kit				NMS-Procurement from PEPFAR, GPR1 and PR2 ongoing.
Partec-CD4 Easy Count Kit				NMS - DFID funding to be used to procure.
Alere Pima CD4 100X Cartridge Kit				NMS - Procurement from PEPFAR underway. UNITAID procurement pending MOU signing.
FACS Count CD4/CD3/CD8 50 TESTS				NMS - Procurement from PEPFAR underway.
HUMACOUNT DILUENT			N/A	
NIHON KOHDEN MEK DILUENT			N/A	
Coulter Diluent			N/A	
Sysmex Cell Pack			N/A	
HUMAN GOT (ASAT) LIQUICOLOR			N/A	
COBAS c 311 ALT			N/A	

Stock Out Risks and Recommendation/Action :

There are currently low stock levels at NMS for key laboratory commodities. Procurement for Determine test kits from PEPFAR and Global Fund underway. PEPFAR procurement of CD4 commodities for the public sector underway. Further DFID funding towards lab commodities has been confirmed and allocated towards HIV test kits, Hematology, clinical Chemistry and General reagents.


Expiry Risks and Recommendation/Action :

For JMS, deliveries from PEPFAR are to arrive in Aug-Sept 2013 to provide for remainder of year.

5. Anti TB Medicines

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)

National/NMS



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Risk of stock out in next three months

Legend

Stock out risk	Below 2 MOS
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 MOS
Adequate stock	Within Min-Max
Stocked out	No product in warehouse

Formulation	NMS	Comments
RHZE tablet 75/150/275/400/ mg		
EH two-week blister strip		
RH (Adult) tablet		In-country stock to be confirmed.
RH (Pediatric) tablet		
RHE (150/75/275 mg)		In-country stock to be confirmed.
RHZ (Pediatric) tablet 60/30/75		
Streptomycin vial 1g		
Capreomycin 1G Vials		To be donated.
Cycloserine 250mg Tablets		To be donated.
Ethionamide 250mg Tablets		
Kanamycin 1G Vials		
Levofloxacin 250mg Tablets		
Moxifloxacin 400mg Tablets		
Paser 4 GM Sachets		To be donated.

Stock Out Risks and Recommendation/Action :

Although central level stock of RH and RHE is low, most health facilities are well stocked. Consignments of RH paed and RHE that arrived recently from GF are to be verified. Global Fund pipeline approved and procurement underway.


Expiry Risks and Recommendation/Action :

Capreomycin, Cycloserine, and Paser at risk of expiry. Quantities at risk of expiry will be loaned other countries.


6. Reproductive Health

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)

Public/NMS



Private



Please see **Months of Stock over 6 Months** to view months of stock including deliveries and consumption over time.

Risk of stock out in next three months

Legend

Stock out risk	Below 2 MOS
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 MOS
Adequate stock	Within Min-Max
Stocked out	No product in warehouse

Formulation	NMS	Private	Comments
Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)			
Implants (Implanon & Jadelle)			
IUD - Copper Containing Device TCU380A			
Combined Oral Contraceptives (Microgynon)			
Progestin-only oral contraceptives			
Male Condom			
Manual Vacuum Aspiration (MVA) Double Valve			
Mama Kit			
Female Condom			
Levonorgestrel 750 mcg Tab (Emerg. Contraceptive)			
Misoprostol 200mcg Tabs			
Gynaecological gloves			

Stock Out Risks and Recommendation/Action :

Key commodities are well stocked. Pipeline for products that are stocked out to be monitored.


Expiry Risks and Recommendation/Action :

No expiry risk to date.

7. Vaccines

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)

National/NMS



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Legend

Stock out risk	Below 2 MOS
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 MOS
Adequate stock	Within Min-Max
Stocked out	No product in warehouse

Risk of stock out in next three months


Formulation	NMS	Comments
Measles Vaccine 10 dose vial	Green	
Bacillus Calmette-Guerin (BCG) 20 dose vial	Yellow	
Human papilloma Virus (HPV) 1 dose vial	Green	
Hepatitis B, 10 dose vial	Black	
DPT-HEPB-HIB 1 dose vial	Black	
Diphtheria, Pertussis	Green	
Tetanus toxoid vaccine (TT) 20 dose vial	Green	
Polio oral trivalent (TopV) 20 dose vial	Red	
Polio Oral Bivalent (BOPV) 20 dose vial	Green	

Stock Out Risks and Recommendation/Action :	Although the polio trivalent stock is inadequate, the bivalent vaccine is sufficiently stocked to cover the current need - no risk of stock outs.
Expiry Risks and Recommendation/Action :	No expiry risks to date.

8. Tracer Medicines

Stock Status (July 1'13) & Total confirmed deliveries in next three months (Jul to Sept'13)

National



Please see [Months of Stock over 6 Months](#) to view months of stock including deliveries and consumption over time.

Legend

Stock out risk	Below 2 MOS
Expiry risk	Below 6 months shelf life
Low risk	Minimum stock
Below min	Below 3 MOS
Adequate stock	Within Min-Max
Stocked out	No product in warehouse

Risk of stock out in next three months

Formulation	Nat'l	Comments
Depo-Provera	Green	
Artemether-Lumefantrine	Green	
Cotrimoxazole 480mg	Yellow	
Oral Rehydration Salts for 1 Litre	Red	
Measles Vaccine	Green	

Stock Out Risks and Recommendation/Action :	Procurement of ORS to be expedited.
Expiry Risks and Recommendation/Action :	No expiry risk to date.

3. Antimalarials

National: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
ACT 20/120mg tab, 24 pack	54,354	3.9	2.9	1.9	1.5	1.8	0.8
ACT 20/120mg tab, 18 pack	12,494	0.0	0.0	0.0	0.0	0.8	0.0
ACT 20/120mg tab, 12 pack	15,849	0.0	0.0	0.0	0.0	0.4	0.0
ACT 20/120mg tab, 6 pack	27,171	0.1	0.0	0.0	0.0	1.3	0.3
Artesunate Injection 60mg/ml	66,543	2.5	1.5	0.5	0.1	0.0	0.0
Quinine HCl Injection, 500mg/2ml	2,000	4.6	3.6	2.6	4.0	3.0	2.0
Sulphadoxine-Pyrimethamine 500/25mg tab*	1,302	1.5	0.5	0.0	1.6	0.6	0.0

NMS: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
ACT 20/120mg tab, 24 pack	51,114	3.7	2.7	1.7	1.3	1.5	0.5
ACT 20/120mg tab, 18 pack	10,753	0.0	0.0	0.0	0.0	0.6	0.0
ACT 20/120mg tab, 12 pack	14,242	0.0	0.0	0.0	0.0	0.2	0.0
ACT 20/120mg tab, 6 pack	25,185	0.0	0.0	0.0	0.0	0.4	0.0
Artesunate Injection 60mg/ml	66,543	2.5	1.5	0.5	0.1	0.0	0.0
Quinine HCl Injection, 500mg/2ml	2,000	4.6	3.6	2.6	4.0	3.0	2.0
Sulphadoxine-Pyrimethamine 500/25mg tab*	1,302	1.5	0.5	0.0	1.6	0.6	0.0

JMS: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
ACT 20/120mg tab, 24 pack	3,240	7.1	6.1	5.1	4.1	7.0	6.0
ACT 20/120mg tab, 18 pack	1,741	3.0	2.0	1.0	0.0	2.3	1.3
ACT 20/120mg tab, 12 pack	1,607	3.3	2.3	1.3	0.3	2.9	1.9
ACT 20/120mg tab, 6 pack	1,986	7.3	6.3	5.3	4.3	>10	>10

Stock Out Risks and Recommendation/Action : Central level stock for ACTs at NMS appear low, however preliminary Medicines Management Supervision reports indicate ~70% facilities are adequately stocked (2+ months). Additional orders have been placed through GF for central level and products are expected by Oct-Dec 2013. Deliveries from Quality Chemicals are also expected in July and October 2013. NMS continues to call off quinine injection, artesunate injection and SP from the framework contract.

Expiry Risks and Recommendation/Action : No expiry risk to date.

4. Laboratory

National: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Malaria Rapid diagnostic kits	50,522	5.4	4.4	4.4	4.5	3.9	2.9
Determine HIV 1/2 Rapid Test kit	9,164	2.3	3.1	2.1	1.1	1.0	0.0
Paritec-CD4 Easy Count kit	2,720	0.0	0.0	0.0	0.0	0.0	0.0
Alere Pima CD4 100X Cartridge Kit	288	0.8	2.3	5.6	4.6	3.6	2.6
FACS Count CD4/CD3/CD8 50 TESTS	10,254	0.0	0.0	0.0	0.0	0.0	0.0
HUMACOUNT DILUENT NIBION KOHDEN MEK	437	0.0	0.0	0.0	0.0	0.0	0.0
DILUENT	282	0.0	0.0	0.0	0.0	0.0	0.0
Coulter Diluent	39	0.0	0.0	0.0	0.0	0.0	0.0
Sysmex Cell Pack	134	0.0	0.0	0.0	0.0	0.0	0.0
HUMAN GDT (ASAT) LIQUICOLOR	140	0.0	0.0	0.0	0.0	0.0	0.0
COBAS c 311 ALT	155	0.0	0.0	0.0	0.0	0.0	0.0

NMS: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Malaria Rapid diagnostic kits	45,868	6.0	5.0	5.2	5.4	4.4	3.4
Determine HIV 1/2 Rapid Test kit	7,600	2.2	3.0	2.0	1.0	1.1	0.1
Paritec-CD4 Easy Count kit	1,738	0.0	0.0	0.0	0.0	0.0	0.0
Alere Pima CD4 100X Cartridge Kit	205	1.0	0.0	5.0	4.0	3.0	2.0
FACS Count CD4/CD3/CD8 50 TESTS	7,165	0.0	0.0	0.0	0.0	0.0	0.0
HUMACOUNT DILUENT NIBION KOHDEN MEK	415	0.0	0.0	0.0	0.0	0.0	0.0
DILUENT	279	0.0	0.0	0.0	0.0	0.0	0.0
Coulter Diluent	39	0.0	0.0	0.0	0.0	0.0	0.0
Sysmex Cell Pack	120	0.0	0.0	0.0	0.0	0.0	0.0
HUMAN GDT (ASAT) LIQUICOLOR	88	0.0	0.0	0.0	0.0	0.0	0.0
COBAS c 311 ALT	144	0.0	0.0	0.0	0.0	0.0	0.0

JMS: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Malaria Rapid diagnostic kits	4,654	7.3	6.3	5.3	4.3	7.6	6.6
Determine HIV 1/2 Rapid Test kit	1,142	4.5	3.5	2.5	1.5	0.5	0.0
Paritec-CD4 Easy Count kit	970	0.0	0.0	0.0	0.0	0.0	0.0
Alere Pima CD4 100X Cartridge kit	60	3.6	>10	>10	>10	>10	>10
FACS Count CD4/CD3/CD8 50 TESTS	2,694	0.0	0.0	0.0	0.0	0.0	0.0
HUMACOUNT DILUENT NIBION KOHDEN MEK	22	0.0	0.8	0.0	5.5	4.5	3.5
DILUENT	3	0.0	7.0	6.0	5.0	4.0	3.0
Coulter Diluent	-	0.0	0.0	0.0	0.0	0.0	0.0
Sysmex Cell Pack	14	0.0	8.7	7.7	6.7	5.7	4.7
HUMAN GDT (ASAT) LIQUICOLOR	52	0.8	0.0	0.0	0.0	0.0	0.0
COBAS c 311 ALT	11	0.0	0.8	9.6	8.6	7.6	6.6

MAUL: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Determine HIV 1/2 Rapid Test kit	422	7.4	>10	>10	9.7	8.7	7.7
Paritec-CD4 Easy Count kit	12	5.6	4.6	3.6	2.6	1.6	0.6
Alere Pima CD4 100X Cartridge Kit	23	4.7	3.7	2.7	1.7	0.7	0.0
FACS Count CD4/CD3/CD8 50 TESTS	395	5.5	4.5	3.5	2.5	1.5	0.5

Stock Out Risks and Recommendation/Action : There are currently low stock levels at NMS for key laboratory commodities. Procurement for Determine test kits from PEPFAR and Global Fund underway. PEPFAR procurement of CD4 commodities for the public sector underway. Further DFID funding towards lab commodities has been confirmed and allocated towards HIV test kits, Hematology, clinical Chemistry and General reagents. For JMS, deliveries from PEPFAR are to arrive in Aug-Sept 2013 to provide for remainder of year.

Expiry Risks and Recommendation/Action : 0

Anti TB Medicines

National: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
RHZE tablet 75/150/225/400/mg EH two-week blister strip, 400/150 mg	52,272	7.3	6.3	5.3	4.3	3.3	2.3
RH (Pediatric) tablet RHE (150/75/275 mg)	6,672	0.0	0.0	0.0	0.0	0.0	0.0
RH2 (Pediatric) tablet 60/30/75 mg	17,136	0.0	0.0	0.0	0.0	0.0	0.0
Streptomycin vial 1g	4,158	7.6	6.6	5.6	4.6	3.6	2.6
Streptomycin vial 1g	23,192	2.8	1.8	0.8	0.0	0.0	0.0

Stock Out Risks and Recommendation/Action : Although central level stock of RH and RHE is low, most health facilities are well stocked. Consignments of RH paed and RHE that arrived recently from GF are to be verified. Global Fund pipeline approved and procurement underway.

Expiry Risks and Recommendation/Action : Capreomycin Cycloserine, and Paser at risk of expiry. Quantities at risk of expiry will be loaned other countries.

Reproductive Health

NMS: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)	236,400	2.4	1.4	0.4	0.0	0.0	0.0
Implants (Implanon & Jadelle)	5,039	7.9	6.9	5.9	4.9	3.9	2.9
IUD - Copper Containing Device (CuI380A)	1,900	5.0	4.0	3.0	2.0	1.0	0.0
Combined Oral Contraceptives (Microonnon)	35,000	0.0	0.0	0.0	0.0	0.0	0.0
Progestin-only oral contraceptives (Microlut/Norgestrel 0.025mg)	3,500	0.0	0.0	0.0	0.0	0.0	0.0
Male Condom (52MM with and without Logo)	5,000,000	9.0	8.0	7.0	>10	>10	9.1
Mama Kit	25,000	0.0	0.0	0.0	0.0	0.0	0.0
Female Condom	68,000	0.0	0.0	0.0	0.0	0.0	0.0
Levonorgestrel 750 mcg Tab (Emergency Contraceptive)	2,001	>10	>10	>10	>10	>10	>10
Misoprostol 200mcg Tabs	33,963	0.0	0.0	0.0	0.0	0.0	0.0

Private: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)	76,100	2.7	6.2	5.2	4.2	3.2	2.2
Implants (Implanon & Jadelle)	19,516	3.4	2.4	3.0	7.5	6.5	5.5
IUD - Copper Containing Device (CuI380A)	3,363	>10	>10	>10	>10	>10	>10
Combined Oral Contraceptives (Microonnon)	32,130	8.6	7.6	6.6	5.6	4.6	3.6
Progestin-only oral contraceptives (Microlut/Norgestrel 0.025mg)	3,339	>10	>10	>10	>10	>10	>10
Male Condom (52MM with and without Logo)	5,734,753	9.4	>10	>10	>10	>10	>10
Female Condom	685,033	0.0	0.0	0.0	0.0	0.0	0.0
Levonorgestrel 750 mcg Tab (Emergency Contraceptive)	873	0.0	0.0	0.0	0.0	0.0	0.0
Misoprostol 200mcg Tabs	116	0.0	0.0	0.0	0.0	0.0	0.0

Stock Out Risks and Recommendation/Action : Key commodities are well stocked. Pipeline for products that are stocked out to be monitored.

Expiry Risks and Recommendation/Action : No expiry risk to date.

Vaccines

National: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Measles Vaccine 10 dose vial	18,333	2.0	1.0	0.0	0.0	0.0	0.0
Bacillus Calmette-Guerrin (BCG), 20 dose vial	22,163	0.6	0.0	0.0	0.0	0.0	0.0
Human papilloma Virus (HPV), 1 dose vial	20,833	2.8	1.8	0.8	0.0	0.0	0.0
Tetanus toxoid vaccine (TT) 20 dose vial	28,142	2.5	1.5	0.5	0.0	0.0	0.0
Polio oral trivalent (TooV) 20 dose vial	33,550	0.0	0.0	0.0	0.0	0.0	0.0
Polio Oral Bivalent (BOPV) 20 dose vial	108	>10	>10	>10	>10	>10	>10

Stock Out Risks and Recommendation/Action : Although the polio trivalent stock is inadequate, the bivalent vaccine is sufficiently stocked to cover the current need - no risk of stock outs.

Expiry Risks and Recommendation/Action : No expiry risks to date.

Tracer Medicines

National: Includes deliveries and expected consumption over 6 month period

Months of Stock	July 1 AMC	Jul 31 2013	Aug 31 2013	Sept 30 2013	Oct 31 2013	Nov 30 2013	Dec 31 2013
END OF MONTH							
Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)	312,500	2.5	2.6	1.6	0.6	0.0	0.0
Artemether-Lumefantrine 20/120mg tab (Green), 24 pack	54,354	3.9	2.9	1.9	1.5	1.8	0.8
Cotrimoxazole 480mg	27,201	0.7	1.7	3.6	3.7	5.3	4.3
Oral Rehydration Salts for 1 Litre	13,823	0.0	0.0	0.0	0.0	0.0	0.0
Measles Vaccine	18,333	2.0	1.0	0.0	0.0	0.0	0.0

Stock Out Risks and Recommendation/Action : Procurement of ORS to be expedited.

Expiry Risks and Recommendation/Action : No expiry risk to date.